ABSTRACT: A human in vivo toxicokinetic model was built to allow a better understanding of the toxicokinetics of folpet fungicide and its key ring biomarkers of exposure: phthalimide (PI), phthalamic acid (PAA) and phthalic acid (PA). Both PI and the sum of ring metabolites, expressed as PA equivalents (PA eq ), may be used as biomarkers of exposure. The conceptual representation of the model was based on the analysis of the time course of these biomarkers in volunteers orally and dermally exposed to folpet. In the model, compartments were also used to represent the body burden of folpet and experimentally relevant PI, PAA and PA ring metabolites in blood and in key tissues as well as in excreta, hence urinary and feces. The time evolution of these biomarkers in each compartment of the model was then mathematically described by a system of coupled differential equations. The mathematical parameters of the model were then determined from best fits to the time courses of PI and PA eq in blood and urine of five volunteers administered orally 1 mg kg À1 and dermally 10 mg kg À1 of folpet. In the case of oral administration, the mean elimination half-life of PI from blood (through feces, urine or metabolism) was found to be 39.9 h as compared with 28.0 h for PA eq . In the case of a dermal application, mean elimination half-life of PI and PA eq was estimated to be 34.3 and 29.3 h, respectively. The average final fractions of administered dose recovered in urine as PI over the 0-96 h period were 0.030 and 0.002%, for oral and dermal exposure, respectively. Corresponding values for PA eq were 24.5 and 1.83%, respectively. Finally, the average clearance rate of PI from blood calculated from the oral and dermal data was 0.09 AE 0.03 and 0.13 AE 0.05 ml h À1 while the volume of distribution was 4.30 AE 1.12 and 6
INTRODUCTION
Folpet (CAS 133-07-3) is a fungicide commonly used in agriculture. It is applied for preventive treatment of plants to control mildew, gray mold, spoilage fungi and wood rot fungi. Folpet is a broad-spectrum contact protectant fungicide which denatures fungal proteins by reacting with their thiol groups (USEPA, 1990; Gordon, 2010) . In humans, it is classified as probable human carcinogen (B2) by the US Environmental Protection Agency (1975, 1990) based on an increased incidence of duodenum tumors in mice chronically exposed to high doses by gavage. It is also considered as a severe irritant of the eyes, skin, nose and throat (Lisi et al., 1987; Guo et al., 1996; Gordon, 2010) .
Although folpet is widely used in agriculture, there is a paucity of data to assess the importance of exposure to this compound in workers (Zainal and Que Hee, 2003; Lebailly et al., 2003) and no biomonitoring data is available in the literature to our knowledge. Moreover, the human toxicokinetics of folpet and its ring metabolites is not fully understood, although this knowledge is necessary to interpret biomonitoring data in field studies.
The majority of toxicokinetic data on folpet have been obtained from in vivo experiments in animals following radiolabeled-dosing as well as in vivo studies. These studies allowed the identification of the main metabolic pathway of folpet ( Fig. 1) . According to these studies, folpet is rapidly split at the N-S link when it is in contact with thiol groups and the reaction is enhanced in acid conditions (Gordon et al., 2001; Gordon, 2010) . From this nonenzymatic process, the ring metabolite phthalimide (PI) and a thiocarbonyl chloride are formed. The initial ring metabolite of folpet, PI, is rapidly hydrolyzed to phthalamic acid (PAA), and mainly in turn to phthalic acid (PA), according to animal studies (Gordon et al., 2001; Zainal and Que Hee, 2003; Canal-Raffin et al., 2008; Gordon, 2010) .
Following oral or intraperitonal administration of ring-labeled folpet, between 90 and 100% of the dose was excreted in the urine of rats over a 24 h period post-dosing. This is based on the study of Wood et al. (1991) showing that 92% of an orally administered dose of 10 mg kg À1 of 14 C-labeled folpet in rats was recovered in urine as 14 C equivalents as compared with 6% in feces. Couch et al. (1977) also indicated that virtually 100% of an intraperitoneal dose of 6 mg kg À1 of 14 C-folpet was recovered in urine as 14 C equivalents and 1.7% in feces over the 24 h period post-dosing.
When PI metabolite was orally administered to rats, about 80% of the administered dose was metabolized and excreted in urine as PAA, 7% was found as PA, and less than 1% of the dose was recovered as PI in urine (Chasseaud et al., 1974) . PAA also represented the main metabolite (i.e. 80%) when labeled 14 C-folpet was orally administered to rats (Chasseaud, 1980) . However, they reported that this metabolite was unstable in urine. The rat studies of Chasseaud (Chasseaud et al., 1974; Chasseaud, 1980) thus showed that PAA and PA appear as quantitatively more important biomarkers than PI. Nonetheless, PA is not a metabolite specific to folpet; it is also a derivative of phthalates, which are ubiquitous molecules in the environment (Blount et al., 2000; Silva et al., 2007) .
Furthermore, in the only dermal penetration study on folpet in animals, Shah et al. (1987) estimated a low dermal absorption fraction, as assessed from analysis of radioactivity in skin and carcasses at 72 h post-application of a low, medium and high dose of 14 C-trichloromethyl labeled folpet in Fisher 344 rats as well as in urine and feces collected over the 72 h period postdosing. On average, 12% of the low dose of folpet was calculated to be absorbed through the skin during that time (application of 0.1 mmol cm À2 on 2.8 and 5.6 cm 2 of young and adult rats, respectively) as compared with only 3 and 1% for the two higher doses (application of 0.5 and 2.7 mmol cm À2 , respectively). With regard to elimination kinetics of PI, Canal-Raffin et al. (2008) reported an elimination half-life of on average 2.5 h in plasma following a single intraperitoneal folpet dose of 10 mg kg À1 in Wistar rats. Ackermann et al. (1978) also estimated a PI half-life of 2 h in rat fetuses following an oral administration of 2.5 mg kg À1 of 15 N-phthalimide to pregnant Wistar-strain albino rats and observed a fast metabolism of PI into PAA. This latter metabolite is then transformed to PA, the final ring metabolite of folpet (Williams and Blanchfield, 1974) . On the other hand, in an in vivo study, Gordon et al. (2001) reported a half-life of labeled-folpet added to human blood of 4.9 s.
Recently, the human time courses of PI in blood and urine of volunteers orally and dermally exposed to folpet were documented (Berthet et al., 2011a (Berthet et al., , 2011b . The objective of the present study was to use these new data to develop a biomathematical model to describe and better understand the toxicokinetics of folpet and its ring metabolites in humans. No such model has been developed so far to describe the toxicokinetics of folpet in humans.
MATERIALS AND METHODS

Data Used for Folpet Model Development
Model development was based on available published metabolism data (Gordon et al., 2001) along with the human timecourse data newly collected in volunteers (Berthet et al., 2011a (Berthet et al., , 2011b . In this controlled experiment of Berthet et al. (2011a Berthet et al. ( , 2011b , healthy volunteers were exposed orally to 1 mg kg À1 of folpet or dermally to 10 mg kg À1 of folpet. The detailed time courses of PI in plasma and in urine were determined during a 96 h period post-dosing. Only urine time courses for PA eq were documented during a 96 h period post-dosing.
Conceptual and Functional Representation of Folpet Model
The kinetics of PI and of PA eq were modeled separately. Conceptual representations are depicted in Figs 2 and 3. Symbols and abbreviations are defined in Table 1 . The mathematical implementation of the models as systems of first-order differential equations is given in Table 2 . In the modeling, it was considered that absorbed folpet is almost instantaneously broken down into its ring and thiol metabolites, leading respectively to PI and 2-thiothiazolidine-4-carboxylic acid (TTCA) metabolites. However, only the pathway leading to the formation of the PI and PA eq biomarkers of exposure was modeled in the current work.
The kinetics of folpet and its ring metabolites (monitored PI and the sum of ring metabolites, PA eq ) was modeled for different routes of exposure: oral, dermal and inhalation. The input doses per unit of time, bioavailable at each site of absorption, the skin, the respiratory tract and the gastrointestinal (GI) tract, were thus respectively described as g dermal (t), g inh (t) and g oral (t). To simulate oral exposure, the model considers compartments for folpet in the GI [G FT (t)] and for the almost instantaneously generated PI (G PI ) and ring metabolites of PI (G PAA and G PA ). Compartments were also used to represent the body burden of experimentally relevant PI, PAA and PA ring metabolites in blood and in tissues in dynamical equilibrium with blood, i.e. tissues that rapidly reach and maintain a fixed ratio with blood [referred to later as the blood compartment B PI (t), B PAA (t) and B PA (t), respectively, for simplicity]. Other nonmonitored ring metabolites [B ON (t)] were also represented as body compartments. Similarly, different excretion compartments were introduced to represent the amounts of PI, PAA and PA metabolites in urine and feces, that is, urinary compartments U PI (t), U PAA (t) and U PA (t), or fecal compartments F PI (t), F PAA (t) and F PA (t); other excretion compartments were added to describe the nonmonitored ring metabolites in urine [U ON (t)] as well as in feces [F ON (t) ].
To simulate the kinetics of PI specifically, PAA and PA compartments were grouped, whereas to simulate the kinetics of PA eq , PI, PAA and PA compartments were lumped. The compartments proposed for body metabolites and for excretion are Table 1. based on the published data and appear sufficient in number to capture, for quantitative assessments, the essential features of the kinetics of the measured metabolites. The linear elimination of PI from blood observed in Berthet et al. (2011a) suggests the absence of a significant storage of folpet in the body, as either an accumulation in lipids or a binding to tissue proteins, and indicates that the whole body distribution of folpet ring metabolites can be described using a single compartment B(t) with first-order elimination.
To simulate the kinetics of PI specifically in blood and urine following dermal absorption, the epidermis and the dermis were represented as separate compartments [SE FT (t) and SD P (t), respectively]. On the other hand, when simulating the kinetics of PA eq , only the epidermal compartment was represented [SE FT (t)], given Rate of PI absorption from the GI into the blood compartment
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Absorbed dose as a function of time the absence of measured blood time course of PA eq , which simplifies the model representation. Thus, all the specific features related to the modeling of dermal kinetics of PI specifically were shadowed by the important amounts of PAA and PA produced at the site of entry and contributing to total PA eq . On the contrary, simulations showed that it was not necessary to add a respiratory tract compartment as an input since the rapid absorption of folpet through the respiratory tract can be viewed kinetically as an almost constant intravenous exposure; thus, inhalation exposures were modeled by direct inputs to the blood compartment and instant fragmentation at the N-S link. This route of exposure was represented simply to show that it can be accounted for in the model. However, there is no available experimental data to date on the time course of ring biomarkers following inhalation exposure to folpet. To insure conservation of mass, all amounts were initially expressed on a mole basis to run the model.
Once the model was functionally represented by systems of differential equations (see Table 2 ), solving these equations yielded the mathematical functions for the time courses of folpet and each of its relevant metabolites in the different compartments. Initial conditions for every compartment were set at zero at starting time of the kinetic modeling.
Determination of Folpet Model Parameters
Model parameters were then determined by best-fit adjustments of the analytical solutions of differential equations to the data of Berthet et al. (2011a Berthet et al. ( , 2011b on the time courses of PI in plasma and PI and PA eq urine of volunteers orally and dermally exposed to folpet. MathCad 14 software was used for this purpose (Parametric Technology Corporation, Needham, MA, USA).
Several procedures exist to best-fit general analytical functions to data sets. For fitting, the algorithm genfit (included in MathCad) was used, which essentially reproduces a least-square minimization. To simplify differential equations and allow a first estimate of parameter values, use was made of the different timescales during which the various biological processes occur (e.g. time of absorption, distribution, metabolism and excretion). Usually, in time, any exposure biomarker of interest finds its way to the final elimination site but on different timescales. The exact body location of a particular metabolite in time will depend on the relative timescales of biological processes. Considering these timescales, in many cases, analytical solutions simplify to single exponential functions. For example, following a single oral exposure, the function describing blood time course of PI [B PI (t)] will completely be driven by the overall rate of elimination of PI from blood (defined by k B ) and will be independent of the oral absorption dynamics (described by the overall disappearance rate of PI from the GI, k G ). In this case, k B < < k G , such that the blood time course of PI [B PI (t)] reduces to:
Similarly, inhaled folpet is promptly absorbed into blood (in the order of minutes) such that the rate of appearance of PI in urine will only be limited by the overall elimination rate of PI from blood.
Moreover, when comparing oral and dermal rate time courses of PI, it was observed that elimination slopes were similar. The parallelism indicates that the final elimination phase of PI following dermal exposure is not governed by skin absorption rate [neither the rate of epidermal diffusion of folpet (k SESD ) nor the diffusion rate of PI almost instantaneously formed in the dermis (k SDB )], but is rather driven by the overall elimination rate of PI from blood, k B , as in the case of oral administration. The same holds true for PA eq .
When looking at the data of Berthet et al. (2011a Berthet et al. ( , 2011b on the elimination rate of PI in blood and urine as a function of time considering a given route of exposure (oral or dermal), it was also shown that elimination slopes were similar for blood and urine, as expected. Therefore, the transfer rate of PI from blood to urine, k BU , can straightforwardly be computed directly from each of the observed blood and urinary time courses of Berthet et al. (2011a Berthet et al. ( , 2011b as follows: 
In other words, for a given route of administration, experimental ratios of cumulative urinary excretion of PI to the area under the curve of blood PI are equal to a constant, defined as k BU [U PI (t)/AUC B PI (t) ∼ k BU ], and thus follow a quasi-constant trend in time. This is the behavior required by our first-order model. Otherwise, the rates of elimination would not be a simple constant, but would rather depend on the amounts of PI present in each compartment.
With regard to the oral route and overall disappearance rate of PI from the GI, represented by k G , it is dependent not only on the absorption of PI from the GI tract into blood (k GB ), but also on the direct elimination of PI in feces (without absorption; k GF ) and GI metabolism of PI to other ring metabolites (k GO ). The transfer rate k GB of PI from the GI to blood can be defined as a proportion f b of the overall disappearance rate of PI from the GI (k G ). The transfer rates k GB , k GO and k GF can in turn easily be defined as follows:
On the other hand, the dermal analogs to these parameters, the rate of epidermal diffusion of folpet (k SESD ), the diffusion rate of PI almost instantaneously formed in the dermis (k SDB ) and the dermal absorption fraction (f abs ), can be calculated in the same manner. For PA eq parameters, a strategy similar to the one used to determine the parameters related to the kinetics of PI specifically can be used. With all the effective transfer rate parameters fixed, the model is completed and ready for sensitivity analysis.
Sensitivity Analysis of Folpet Model Parameters
There are several tests to measure the sensitivity of a particular parameter on a given function. Sensitivity analysis is the mathematical procedure aiming at assessing how much the value of a dependent function is modified as one changes a particular independent degree of freedom, while keeping all the remaining parameters unaffected. One can measure this effect by means of the normalized sensitivity coefficient defined as:
This coefficient measures changes in model simulations defined by f with respect to the change d of the parameter b under assessment. If the sensitivity coefficient is zero, the kinetic model is independent of the given parameter. If the coefficient diverges to infinity, simulation is highly sensitive to the model parameter and, therefore, the mathematical model is unstable. In our case, we have allowed all the degrees of freedom to vary a conservative standard deviation around the mean experimental data.
With this range of variability, the sensitivity coefficient for every degree of freedom in our model was calculated. This coefficient was computed for every single experimental time point and average values were then calculated.
Model Evaluation
The model developed using the data of Berthet et al. (2011a Berthet et al. ( , 2011b was evaluated using two independent sets of experimental data, namely plasma and urine time course data following both oral and dermal exposure. The kinetics of two different biomarkers was also modeled, namely PI specifically and PA eq , hence allowing verification of the consistency between both mathematical simulations independently. Table 3 , has corroborated our principal hypotheses about folpet kinetics, namely (a) it is almost instantaneously broken down to PI and its counterpart thiol metabolite at the site of entry (GI following oral exposure and dermis following dermal application); (b) folpet ring metabolites are rapidly absorbed into blood and then readily eliminated from the body following both oral and dermal exposures; (c) the skin dermis does not retain folpet ring metabolites, as the dermal absorption rate was found to be larger than the overall elimination rate of metabolites from blood; (d) folpet is not stored in body compartments; (e) PI is a specific biomarker of folpet exposure, but is only a minor metabolite; and (f) the kinetics of PI is similar to that of total ring metabolites, expressed as PA eq , but the latter is a much more abundant biomarker, although less specific to folpet.
RESULTS
Development of Folpet Model and Simulations of Experimental Kinetic Data
Overall elimination half-life of PI from blood was found to be 39.9 h following oral exposure as compared with 34.3 h following dermal application. By comparison, the overall elimination half-life of PA eq was found to be 28.0 h following oral administration as compared with 29.3 h after dermal application. These values indicate a fairly rapid tissue distribution, biotransformation and elimination of both PI and PA eq , with values in the same range for both biomarkers (PI and PA eq ) and both routes of entry (oral and dermal). According to the model, four different processes contribute to total elimination rate of PI specifically from blood: biotransformation to other ring metabolites, fecal excretion, renal clearance and finally distribution to nonobserved organs. Of all the preceding mechanisms, renal clearance contributes mainly to the overall elimination rate of PI from blood (85.5%) following oral administration. On the other hand, following dermal application, renal clearance contributed only to 27.0% of PI overall elimination from blood, the remaining being attributed to metabolism of PI into derivatives or fecal excretion of blood PI.
When modeling the kinetics of total ring metabolites, it was not possible to extract the exact contribution of the renal and fecal clearance to the overall elimination rate of PA eq from the blood compartment, because only the time course of PA eq in urine was experimentally available (not blood). However, following oral exposure in volunteers, considering that the elimination of PA eq in urine is almost complete 96 h post-exposure, it can roughly be estimated with the model that 24.5% of ingested folpet is eliminated as PA eq in urine while the remaining 75.5% should be either eliminated as PA eq in feces or found as unaccounted metabolites. Similarly, with the model, 7.42% of folpet was predicted to be absorbed through the skin, with 24.7% of absorbed amounts being excreted as PA eq in urine and 75.3% as PA eq in feces or as unaccounted metabolites in the body.
From the time course curves of PI in blood, other calculated parameters include the discrete version of the area under the concentration-time curve (AUC), the area under the first moment of concentration-time curve (AUMC), the clearance from blood (Cl), the apparent volume of distribution (V d ) and the mean residence time (MRT) as presented in Table 4 . When looking at the predicted blood time course of PI [described by the analytical function B PI (t)], the maximum level for an oral exposure was obtained at around 4 h (and representing 0.0325% of ingested dose according to simulations as compared with 0.0397% of dose experimentally observed). This was simply due to competing rates of oral absorption and elimination of PI from the blood compartment. By comparison, following dermal application, this concomitant impact of absorption and elimination rates caused the blood profile to present a maximum level of PI at around 10 h. After dermal exposure, maximum level was lower than after ingestion (representing 0.00697% of applied dose according to simulations as compared with 0.0123% of dose experimentally observed), owing to the small dermal absorption fraction, and time to maximum level was slightly delayed by the transfer rate through the skin.
Furthermore, it is interesting to note that the time course of PI in blood was parallel to that of PI urinary excretion rate, for both oral and dermal exposures, which indicates that the kinetics of PI is well described by considering solely the compartments B PI (t) and U PI (t). For example, in the oral model, if there were some crucial phenomenon occurring in the kidney, the blood and urinary time profiles would not necessarily evolve in parallel. Moreover, a single exponential elimination was apparent from slopes of the time course curves of PI in blood. This is an important indicator of the absence of any kind of accumulation of PI in the body, which would then be reflected by at least a bi-exponential decrease rather than a mono-exponential elimination.
Regarding biotransformation of PI into its derivatives more specifically, it was taken to occur at the site of entry (GI or dermis following oral and dermal exposure, respectively) or as soon as PI reaches systemic blood. Given that PI is simulated to be largely metabolized to derivatives in the GI tract, the fraction of PI itself absorbed from the GI into blood is found to be very small (0.0353%). As for the importance of metabolism of PI to other ring metabolites in blood, it could not be determined precisely for lack of fecal time course data. Therefore, only the concomitant contribution of metabolism of PI to derivatives and fecal excretion to the overall elimination of PI from the blood compartment could be computed, namely, 14.5% for oral exposure and 73.0% for dermal application (with the rest corresponding to renal clearance of PI).
In the particular case of model simulation of skin absorption and ensuing dermal kinetics of PI, separate skin subcompartments had to be described. The first segment (SE FT for folpet) is the one that effectively represents the dynamics of the absorption of folpet through the epidermis. By definition, the first segment describes the passive diffusion of unchanged folpet. The effective rate of Table 3 . Model parameter values determined from the average blood and urinary time course data of Berthet et al. (2011a Berthet et al. ( , 2011b diffusion of folpet was found to be K SESD = 2.22 Â 10 À1 h
À1
. The second segment (SD PI for PI) simply represents the dermis, which is irrigated by blood and therefore allows for the folpet to instantaneously biotransform into PI. Thus, this compartment accounts for the formation of PI and its rate of transfer from skin to blood with a half-life of 51.5 min. To model the toxicokinetics of PA eq and not just PI specifically following dermal exposure, the toxicokinetic parameters describing skin absorption of folpet (absorption fraction and absorption rate) were taken to be the same as those calculated from the blood time course curves of PI; therefore, the dermal absorption fraction was set to be 0.0742 and the dermal absorption rate of folpet was taken to be k SESD = 2.22 Â 10 À1 h À1 . Interestingly, when comparing this value with the overall rate of appearance of PI in blood following oral exposure (k G , otherwise defined as the rate of disappearance from the GI), which is calculated to be 1.06 h À1 , the dermal absorption rate appears quite rapid.
Sensitivity Analysis of Model Parameters
Sensitivity coefficients were computed for every single experimental time point and average values were calculated as reported in Table 5 . The most sensitive parameters were those expected to shift the simulations by simple y-axis translation (the oral absorption fraction f b , the dermal absorption fraction f abs and the rate of elimination of PI or PA eq from blood to urine k BU and k′′ BU ), while the shapes of the curves were mostly sensitive to changes in the slope defined by the overall elimination rate of PI or PA eq from blood, k B or k′′ B , the overall disappearance rate of PI or PA eq from the GI after oral exposure, k G and k′′ G , and the dermal absorption rate k SESD . With respect to k SDB , the analysis also showed an important effect of its variation on the time course curves. Owing to the fact that folpet is rapidly absorbed, any variation in the transfer rates from the epidermis to dermis and/or variation in the metabolism at the site of entry will result in a phenomenon similar to a time delay or a translation on the time-axis.
DISCUSSION
This study allowed a better understanding of the kinetics of PI, PA eq as potential key biomarkers of exposure to folpet. It enabled to relate an internal dose of folpet to the time courses of PI and PA eq biomarkers in available biological fluids (such as blood and urine). Effective compartment models, with two mathematical components, were built to represent the kinetics of those biomarkers. The toxicokinetic models provided a very good approximation of the experimental time course data of Berthet et al. (2011a Berthet et al. ( , 2011b in volunteers orally and dermally exposed to folpet under controlled conditions. According to model simulations and in line with Gordon (2010) , the first biological process governing the kinetics of folpet is its almost instantaneous nonenzymatic breakdown into PI and thiophosgene. PI biotransformation into PA and PAA at the sites of entry (GI for oral exposure and dermis for dermal exposure) was also found to be relatively rapid. Once in blood, PI elimination was found to be fairly rapid (k B = 31.6 h) and was modeled to occur through metabolism to PAA and PA, renal clearance and fecal excretion. On the other hand, when simulating the time course of PA eq , which accounts for total ring metabolites, elimination from blood was dependent only on renal and biliary clearance. Levels of PI and PA eq in nonmonitored tissues (such as liver, kidney or lung) were taken to rapidly reach a dynamical equilibrium with blood and were theoretically assumed to evolve in parallel. PI and PA eq in blood and these tissues were thus lumped under a single compartment defined as PI or PA eq blood compartment for simplicity.
The excellent agreement between model simulations and measured blood and urinary time course data following an oral and dermal exposure in volunteers, considering a single-exponential model for PI and PA eq elimination from blood and tissues in dynamical equilibrium with blood, also confirmed the lack of significant storage of the parent compound or the metabolites in any tissue components (e.g. adipose tissues, protein binding as well as other body lipid components). This is in line with animal studies showing negligible accumulation of phthalimide moieties (Couch et al., 1977; Ackermann et al., 1978) in tissues following oral or intraperitoneal administration of labeled folpet.
In the particular case of model simulation of an oral exposure in humans, a single GI compartment was introduced to describe site of entry kinetics of PI and PA eq and account for GI metabolism, absorption in blood as well as the intestinal transit time, which delays the appearance of PI and PA eq in feces (in the latter case with a half-life of 39.1 min for PI specifically and 31 min for PA eq ). Following folpet ingestion in humans, even though it is almost instantaneously broken down into PI in the GI, only a very small fraction of PI reaches the blood (0.0353% according to the model). This result can be a priori be understood as an efficient elimination of folpet and/or PI directly through feces without being absorbed. However, experimental data in rats show that, following oral or intraperitonal administration of ring-labeled folpet, between 90 and 100% of the administered dose was excreted in the urine of rats over a 24 h period post-dosing (Wood et al., 1991; Couch et al., 1977) . Therefore, the small amounts of PI transferred to blood following ingestion of folpet 
The first moment of concentration-time curve is approximated by:
The clearance of the blood module was determined by: Cl = dose/AUC. Toxicokinetic modeling of folpet biomarkers can only be explained by a rapid biotransformation of PI into PAA and PA in the GI, the latter of which are subsequently readily absorbed into systemic blood.
It is also noteworthy that the mathematical model did not require consideration of an enterohepatic recycling of any ring metabolite, as no feedback features were apparent from the available blood time course data in volunteers (Berthet et al., 2011a (Berthet et al., , 2011b . Therefore, contribution of this process to the overall excretion dynamics was found to be negligible and thus had no impact on the kinetics of distribution and elimination of these metabolites.
On the other hand, to simulate dermal exposure, PI in the skin was represented by two subcompartments. As previously mentioned, the first segment simply represents passive diffusion of folpet through the epidermis (3.13 h), while the second accounts for the actual formation, metabolism and dynamics of PI in the dermis with a half-life of 51.5 min. The latter timescales show the rapid skin absorption when exposed to folpet in humans. While folpet dermally absorbed is quickly metabolized at the site of entry and readily distributed to the systemic blood compartment, only a small fraction of applied folpet penetrates the skin barrier (7.42% according to the model). This is in agreement with the rat data from the only dermal penetration study on folpet in animals, showing a low dermal absorption fraction (Shah et al., 1987) . With respect to model simulation of PA eq kinetics following dermal exposure, the toxicokinetic parameters describing skin absorption of folpet (absorption fraction and absorption rate) were taken to be the same as those calculated from the blood time course curves of PI.
Once applied folpet reached the dermis, which is irrigated by blood, it was modeled to be almost instantaneously metabolized to PI. This is supported by the available in vivo data of Gordon et al. (2001) , showing that the half-life of 14 C-labeled folpet (1 mg l À1 ) added to human blood was estimated to be on the order of seconds (4.9 s). In the model, PI is in turn mostly metabolized to PAA and PA at the site of entry. The PI reaching the blood compartment is predicted to be eliminated in large part by renal clearance (representing 88.5% of overall elimination according to the model) while the rest (11.5%) represents PI metabolism and fecal excretion. Most plausibly, fecal excretion is very limited according to animal data (Couch et al., 1977) . Unfortunately, even if our toxicokinetic model accounted for these processes, the experimental data available in humans did not include fecal matrix.
With respect to renal clearance more specifically, the parallelism observed between the blood and the urine compartments is clear evidence that the kidney is in complete kinetic equilibrium with blood and that no particular retention mechanism occurs for PI in the kidney. Furthermore, according to model simulations, no saturation in absorption, distribution, metabolism of PI or urinary excretion was apparent at the 1 mg kg À1 oral and 10 mg kg À1 dermal doses administered to subjects.
CONCLUSION
This study succeeded in developing a toxicokinetic model for PI and the sum of ring metabolites PI, PAA and PA, which provided a close match to a large set of experimental time course data in two biological matrices of exposed volunteers. This modeling provided new insights into the mechanistic determinants of folpet kinetics that can improve understanding and use of ring metabolites as proper biomarkers. 
